Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) have announced the presentation of new data for their Alzheimer’s drug Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use.
These data were presented at the annual Clinical Trials on Alzheimer’s Disease conference held in Boston, Massachusetts, USA.
An intravenous infusion (IV) of Leqembi was approved in July, but the companies are also seeking approval for a subcutaneous (SC) version of the drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze